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Low plasma homoarginine (HA) is an emerging biomarker for cardiovascular dis-ease and an independent predictor of mortality in patients with heart failure.1 Plas-ma levels appear to reflect cardiac dysfunction, positively correlating with ejection 
fraction and inversely with circulating brain natriuretic peptide.2 However, whether this 
outcome is a bystander or cause-and-effect has yet to be established. Within the 
context of stroke, a direct causal relationship has been inferred because normal mice 
pretreated with 14 mg/L HA had a smaller stroke size.3 In the present study, we show 
for the first time that dietary supplementation with HA improves cardiac function in the 
setting of chronic heart failure, suggesting a novel preventive strategy and inferring 
that low HA levels may be inherently detrimental because of a loss of this effect.
We first confirmed that oral supplementation of C57BL/6J mice (Harwell, UK) 
with 14 mg/L L-HA hydrochloride (Sigma-Aldrich) in the drinking water for 4 weeks 
increased HA concentrations in both plasma (0.29±0.03 vs 0.89±0.07 µmol/L) 
and myocardial tissue (17.6±2.7 vs 48.8±6.8 nmol/g protein; n=5–10; P<0.01 for 
both), demonstrating a strong correlation between levels in plasma and myocardium 
(r=0.74, P<0.01). This dose did not significantly alter cardiac haemodynamic pa-
rameters or body weight and was chosen to match the dosing strategy previously 
shown to be cerebroprotective.3
To investigate the influence of HA supplementation on heart failure development, 
adult female C57BL/6J mice were given drinking water with or without 14 mg/L 
HA for 4 weeks before myocardial infarction surgery and throughout the remaining 
6 weeks follow-up. Echocardiography was performed 4 weeks after surgery to 
exclude infarcts <25% because these mice do not develop heart failure. High-res-
olution cine-magnetic resonance imaging under isoflurane anesthesia was applied 
in vivo 5.5 weeks after surgery to assess infarct size, left ventricular (LV) structure, 
mass, and volumes. After 6 weeks, haemodynamic measurements were obtained 
by LV catheterization and contractile reserve assessed under maximal dobutamine 
infusion (16ng/g body weight/min) via the jugular vein. All surgery and in vivo phe-
notyping was as previously described.4 Cardiac blood, lungs, and scar-free LV tis-
sue were collected and stored at −80°C. Myocardial and plasma HA concentrations 
were measured using tandem-mass spectrometry.3 This investigation was approved 
by the Ethical Review Committee at the University of Oxford and conforms to the UK 
Animals (Scientific Procedures) Act, 1986, incorporating Directive 2010/63/EU.
No difference was found in the overall survival between groups (control myo-
cardial infarction 64% vs HA supplementation 68%, P=0.69). For all subsequent 
analyses, experimental groups were retrospectively matched for infarct size, 
which is necessary to determine the effect of HA on heart failure development 
independent of effects on myocardial injury.4 Cine-magnetic resonance imaging 
revealed profound LV remodeling, which is indicative of heart failure (ie, dilatation 
and hypertrophy), but to a similar extent in both control and HA-supplemented ani-
mals (Table). Similarly, global function assessed by magnetic resonance imaging 
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(eg, ejection fraction) was severely impaired but did not 
differ between groups most likely because magnetic 
resonance imaging could only be performed under 
basal (nonstimulated) conditions. In contrast, haemody-
namic measures of isovolumetric function were better 
preserved with HA supplementation, as evidenced by 
higher LV contractility (dP/dtmax) at baseline and upon 
β-adrenergic stimulation, manifesting as preserved con-
tractile reserve (∆dP/dtmax). Furthermore, diastolic indi-
ces (dP/dtmin, tau) were also improved under stimulated 
conditions in the HA-supplemented animals (Table). 
These findings are unlikely to reflect altered loading 
conditions because markers for afterload (LV systolic 
pressure) and preload (LV end-diastolic pressure) did 
not differ significantly between groups, and tau is rela-
tively load-insensitive.
Conceivably, our results will stimulate further re-
search. For example, the precise molecular mechanism 
remains elusive, and it has yet to be established whether 
presupplementation is necessary or HA has an addition-
al effect on infarct size. Maintaining functional reserve 
would clearly be desirable for patient quality of life, but 
whether this is truly beneficial in the long term will need 
to be tested in the clinical setting. In this context, it is 
notable that a beneficial effect was obtained from a 3-fold 
increase in plasma HA using a human dose equivalent 
Table. In Vivo Cardiac Function 6 Weeks After Myocardial Infarction (MI) in 
Female C57BL/6J Mice With (+HA) and Without (−HA) Dietary Homoarginine 




P  Value−HA +HA
Cine-Magnetic Resonance Imaging (n=19) (n=23)  
 Infarct size (%) 39.3±9.1 39.8±7.0 0.84
 Heart rate (bpm) 461±34 454±34 0.54
 Ejection fraction (%) 17±5 15±5 0.39†
 End diastolic volume (µL) 140±35 147±28 0.40†
 End systolic volume (µL) 118±36 125±29 0.50
 Stroke volume (µL) 22±5 22±5 0.90
 Cardiac output (mL/min) 10 130±2517 9893±2653 0.67†
Haemodynamics (baseline) (n=19) (n=23)  
 LV systolic pressure (mm Hg) 84±6 88±6 0.06
 LV end-diastolic pressure (mm Hg) 14.6±5.3 13.3±4.2 0.36
 Tau (ms) 15.0±2.8 13.4±3.4 0.11
 dP/dt
max
 (mm Hg/s) 4753±1073 5515±1292 0.03†*
 dP/dt
min
 (mm Hg/s) −3308±998 −4029±1447 0.051†
Haemodynamics (stimulated‡) (n=19) (n=23)  
 LV systolic pressure (mm Hg) 84±6 88±7 0.06
 LV end-diastolic pressure (mm Hg) 13.5±5.3 10.8±3.9 0.069
 Tau (ms) 11.8±2.4 9.9±2.5 0.014*
 dP/dt
max
 (mm Hg/s) 5710±1791 7421±2643 0.006†*
 dP/dt
min
 (mm Hg/s) -4048±1358 -5357±2038 0.009†*
 Δ dP/dt
max
 (mm Hg/s) 956±881 1906±1570 0.014†*
Postmortem morphology (n=19) (n=23)  
 Tibial length (mm) 18.2±0.3 18.3±0.2 0.17
 Lung/tibial length (mg/mm) 9.2±2.9 9.6±2.5 0.28†
 LV/tibial length (mg/mm) 7.1±0.8 7.7±1.0 0.06
All values are presented as mean±SD. *P<0.05 for −HA versus +HA using Student’s t test when normally 
distributed or †Mann-Whitney-U test when normality assumption is violated. Haemodynamic measurements 





, relaxation; Δ dP/dt
max
, contractile reserve; and LV, left ventricle.
Atzler et al
January 24, 2017 Circulation. 2017;135:400–402. DOI: 10.1161/CIRCULATIONAHA.116.025673402
of ≈250 mg daily. Recently, we investigated kinetic and 
dynamic properties of oral HA supplementation in healthy 
humans demonstrating a 7-fold elevation in plasma HA 
levels when 125 mg HA was given daily for 4 weeks,5 
suggesting that a relatively low dose would be sufficient 
to elevate plasma HA into the therapeutic range for at-
risk patients. This contrasts with the known pharmaco-
kinetic profile for L-arginine supplementation, suggesting 
that HA is not a straightforward substitution for L-arginine 
metabolism.5 Nevertheless, future studies should deter-
mine the effect of HA on nitric oxide bioavailability.
Our study questioned whether, for the same extent 
of myocardial injury, dietary HA supplementation modi-
fies the subsequent development of chronic heart fail-
ure. Specifically, we can conclude that HA did not alter 
structural LV remodeling after myocardial infarction but 
that dietary HA supplementation preserved contractile 
reserve, with treated hearts maintaining higher responses 
to β–adrenergic stimulation. This finding suggests that 
HA is more than a bystander biomarker because higher 
levels directly influence heart failure pathophysiology. 
Because it is safe, cheap, and easily administered,5 di-
etary supplementation with homoarginine represents a 
promising approach for clinical translation.
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